home
sitemap
print
recommend

2010 Portfolio News


News from the portfolios of HBM BioVentures and HBM BioCapital

30.06.2010 HBM Partners to launch new M&A Report at BioBusiness Network conference
(29-30 September 2010, Geneva)
23.06.2010 Anthera enrolls first patients in pivotal Varespladib phase 3 clinical study
02.06.2010 Nabriva initiates phase II of pleuromutilin antibiotic BC-3781
07.06.2010 PTC Therapeutics awarded $5.4 million grant from the Wellcome Trust
17.05.2010 Mpex Pharmaceuticals presents positive phase 2 clinical trial results of
Aeroquin (MP-376) treatment in Cystic Fibrosis patients
11.05.2010 FDA Advisory Committee to review Lux Biosciences' Uveitis candidate Luveniq
27.04.2010 Asthmatx receives FDA approval for the Alair Bronchial Thermoplasty System
19.04.2010 Interventional Spine announces first US implant of RENEW for lumbar spinal
stenosis
04.03.2010 Anthera Pharmaceuticals completes Initial Public Offering
30.03.2010 Lux Biosciences' Luveniq receives FDA priority review
02.03.2010 Abbott and Enanta announce advancement of Hepatitis C collaboration
02.03.2010 Lux Biosciences receives acceptance of Luveniq MAA filing from European
Medicines Agency
04.02.2010 Lux Biosciences files for Luveniq approval in US and Europe for noninfectious
Uveitis
20.01.2010 Kolltan Pharmaceuticals closes $ 10 million series B related financing
12.01.2010 Asthmatx pivotal trial manuscript for Bronchial Thermoplasty published in the
American Journal of Respiratory and Critical Care Medicine
11.01.2010 GSK exercises option to progress development of ChemoCentryx's Traficet-EN
for the treatment of inflammatory bowel diseases